schizophrenia. Schizophrenia
Conditions
Interventions
Intervention 1: Patients are required to have treated with a stable dose of risperidone (4-6mg/day) as their primary antipsychotic treatment and receive ondansetron (4-8 mg/day) for a minimum period
Treatment - Drugs
Placebo
Patients are required to have treated with a stable dose of risperidone (4-6mg/day) as their primary antipsychotic treatment and receive ondansetron (4-8 mg/day) for a minimum period of 8 weeks.
The control group receive the placebo in addition to risperidone (4-6 mg/day).
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: patients who have been treated with a stable dose of risperidone as their primary antipsychotic treatment for a minimum period of 8 weeks before entry into the study. Exclusion criteria: Patients who had any medical diagnoses (including ECG conduction abnormalities, neurological disorder, or an active seizure) or were receiving medications that may have affected cognitive performance; Subjects who met the criteria for a DSM IV diagnosis of alcohol or substance abuse (other than for nicotine) within the last month or the criteria for DSM-IV alcohol or substance dependence (other than for nicotine) within the last 6 months; Pregnant or lactating women and those of reproductive age without adequate contraception; psychotropic medications were not allowed for the duration of the study: anticholinergics, sedating antihistaminic, antidepressants, mood stabilizers, or a second antipsychotic (as adjuvant therapy).
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Negative symptom. Timepoint: base line,weeks 4,8. Method of measurement: PANSS. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Soozan Soluti
Ibn-e-sina Hospital, Mashhad University of Medical Sciences
Outcome results
None listed